Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

This study has been completed.
Sponsor:
Collaborator:
Forest Laboratories
Information provided by (Responsible Party):
Ironwood Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00938717
First received: July 12, 2009
Last updated: October 9, 2013
Last verified: October 2013
  Purpose

The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).


Condition Intervention Phase
Irritable Bowel Syndrome With Constipation
Drug: Linaclotide or Matching Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 26 Weeks in Patients With Irritable Bowel Syndrome With Constipation

Resource links provided by NLM:


Further study details as provided by Ironwood Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    A patient is considered to be a 9 out of 12 week APC responder if, for at least 9 out of the first 12 weeks of the treatment period, the patient had at least 3 CSBMs, had an increase of at least 1 CSBM from baseline, and had a decrease of at least 30 percent in their Abdominal Pain (AP) score from baseline during a particular week.

    The AP score assesses patient's worst AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP.

    SBM is defined as a bowel movement that occurs in the absence of laxative, enema, or suppository use on either the calendar day of the bowel movement or the calendar day before the bowel movement. CSBM is defined as an SBM associated with a sense of complete evacuation.


  • Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    A patient is considered to be a CSBM 3+1 responder if, for at least 9 out of the 12 weeks of the treatment period, the patient had at least 3 CSBMs and experienced an increase of at least 1 CSBM from baseline during a particular week.

    A CSBM was defined as a Spontaneous Bowel Movement (SBM) that was associated with a sense of complete evacuation.

    An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.


  • Abdominal Pain Responder, 9 Out of 12 Weeks [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    A patient is considered to be an abdominal pain responder if, for at least 9 out of the 12 weeks of the treatment period, they experienced a decrease of at least 30 percent in the mean abdominal pain score from baseline during a particular week.

    The Abdominal Pain score assesses patient's worst abdominal pain in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no abdominal pain and 10 represents very severe abdominal pain.


  • Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    A patient is considered to be a 6 out of 12 week APC responder if, for at least 6 out of the first 12 weeks of the treatment period, the patient had an increase of at least 1 CSBM from baseline, and had a decrease of at least 30 percent in their Abdominal Pain (AP) score from baseline during a particular week.

    The AP score assesses patient's worst AP in the past 24 hours using an 11-point scale (from 0-10), where 0 represents no AP and 10 represents very severe AP.

    SBM is defined as a bowel movement that occurs in the absence of laxative, enema, or suppository use on either the calendar day of the bowel movement or the calendar day before the bowel movement. CSBM is defined as an SBM associated with a sense of complete evacuation.



Secondary Outcome Measures:
  • 12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    The change from baseline in 12-week CSBM frequency (i.e., weekly CSBM frequency over the first 12 weeks of the Treatment Period).

  • 12-Week Spontaneous Bowl Movement (SBM) Frequency [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    The change from baseline in 12-week SBM frequency (i.e., weekly SBM frequency over the first 12 weeks of the Treatment Period).

  • 12-Week Change in Stool Consistency [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    The consistency of each BM was assessed by patients using the 7-point Bristol Stool Form Scale (BSFS) from 1 to 7.

    1. = separate hard lumps like nuts [difficult to pass]
    2. = sausage shaped but lumpy
    3. = like a sausage but with cracks on surface
    4. = like a sausage or snake, smooth and soft
    5. = soft blobs with clear-cut edges [passed easily]
    6. = fluffy pieces with ragged edges, a mushy stool
    7. = watery, no solid pieces [entirely liquid]).

  • 12-Week Change in Severity of Straining [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Straining is measured on a 5-point scale where a value of 1 is "not at all" and a value of 5 is "an extreme amount".

  • 12-Week Change in Abdominal Pain Score [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.

  • 12-Week Change in Abdominal Discomfort [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Abdominal discomfort was assessed on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe".

  • 12-Week Change in Bloating [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    Bloating was assessed on an 11-point scale where a value of 0 is "none" and a value of 10 is "very severe".

  • Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    A patient is considered to be a CSBM responder if, for at least 6 out of the 12 weeks of the treatment period, an increase of at least 1 CSBM per week from baseline was experienced.

  • Abdominal Pain Responder for 6 Out of 12 Weeks [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]
    A patient is considered to be an AP responder if, for at least 6 out of the first 12 weeks of the treatment period, the patient had a decrease of at least 30 percent in their Abdominal Pain score from baseline during a particular week.

  • 12-Week Percent of Abdominal Pain-free Days [ Time Frame: Change from Baseline to Week 12 ] [ Designated as safety issue: No ]

    Abdominal pain free (APF) days are those days where the patient reported a score of '0' for abdominal pain at its worst.

    Abdominal Pain at its worst (in the last 24 hours) is based on an 11-point scale where 0 represents no abdominal pain and 10 represents very severe abdominal pain.



Enrollment: 805
Study Start Date: July 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Linaclotide or Matching Placebo
Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
Experimental: 290 μg Linaclotide Drug: Linaclotide or Matching Placebo
Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings
  • Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests
  • Patient meets protocol criteria for diagnosis of IBS-C
  • Patient demonstrates continued IBS-C through Pretreatment Period
  • Patient is compliant with IVRS

Exclusion Criteria:

  • Patient has history of loose or watery stools
  • Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain
  • Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility
  • Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00938717

  Hide Study Locations
Locations
United States, Alabama
Ironwood Investigational Site
Birmingham, Alabama, United States, 35209
Ironwood Investigational Site
Huntsville, Alabama, United States, 35801
United States, Arizona
Ironwood Investigational Site
Phoenix, Arizona, United States, 85014
Ironwood Investigational Site
Tempe, Arizona, United States, 85282
Ironwood Investigational Site
Tucson, Arizona, United States, 85710
Ironwood Investigational Site
Tucson, Arizona, United States, 85741
United States, Arkansas
Ironwood Investigational Site
Sherwood, Arkansas, United States, 72120
United States, California
Ironwood Investigational Site
Anaheim, California, United States, 92801
Ironwood Investigational Site
Chula Vista, California, United States, 91910
Ironwood Investigational Site
Encinitas, California, United States, 92024
Ironwood Investigational Site
Garden Grove, California, United States, 92840
Ironwood Investigational Site
Laguna Hills, California, United States, 92653
Ironwood Investigational Site
Orange, California, United States, 92868
Ironwood Investigational Site
San Carlos, California, United States, 94070
Ironwood Investigational Site
San Diego, California, United States, 92108
Ironwood Investigational Site
San Diego, California, United States, 92103
Ironwood Investigational Site
San Diego, California, United States, 92123
United States, Colorado
Ironwood Investigational Site
Colorado Springs, Colorado, United States, 80904
United States, Connecticut
Ironwood Investigational Site
Bristol, Connecticut, United States, 06011
United States, Florida
Ironwood Investigational Site
Boynton Beach, Florida, United States, 33426
Ironwood Investigational Site
Hollywood, Florida, United States, 33021
Ironwood Investigational Site
Inverness, Florida, United States, 34452
Ironwood Investigational Site
Jacksonville, Florida, United States, 32205
Ironwood Investigational Site
Jacksonville, Florida, United States, 32207
Ironwood Investigational Site
Lauderdale Lakes, Florida, United States, 33319
Ironwood Investigational Site
Miami, Florida, United States, 33156
Ironwood Investigational Site
Pinellas Park, Florida, United States, 33782
Ironwood Investigational Site
Tampa, Florida, United States, 33607
United States, Georgia
Ironwood Investigational Site
Newnan, Georgia, United States, 30263
United States, Illinois
Ironwood Investigational Site
Peoria, Illinois, United States, 61602
United States, Indiana
Ironwood Investigational Site
Anderson, Indiana, United States, 46011
United States, Iowa
Ironwood Investigational Site
Clive, Iowa, United States, 50325
Ironwood Investigational Site
Davenport, Iowa, United States, 52807
United States, Kansas
Ironwood Investigational Site
Mission, Kansas, United States, 66202
Ironwood Investigational Site
Overland Park, Kansas, United States, 66215
Ironwood Investigational Site
Topeka, Kansas, United States, 66606
United States, Louisiana
Ironwood Investigational Site
Baton Rouge, Louisiana, United States, 70809
Ironwood Investigational Site
Metairie, Louisiana, United States, 70006
Ironwood Investigational Site
Monroe, Louisiana, United States, 71201
Ironwood Investigational Site
Shreveport, Louisiana, United States, 71103
United States, Maryland
Ironwood Investigational Site
Annapolis, Maryland, United States, 21401
Ironwood Investigational Site
Baltimore, Maryland, United States, 21215
Ironwood Investigational Site
Hollywood, Maryland, United States, 20636
Ironwood Investigational Site
Laurel, Maryland, United States, 20707
United States, Michigan
Ironwood Investigational Site
Chesterfield, Michigan, United States, 48047
Ironwood Investigational Site
Traverse City, Michigan, United States, 49684
Ironwood Investigational Site
Troy, Michigan, United States, 48098
United States, Minnesota
Ironwood Investigational Site
Plymouth, Minnesota, United States, 55446
United States, Mississippi
Ironwood Investigational Site
Jackson, Mississippi, United States, 39202
Ironwood Investigational Site
Tupelo, Mississippi, United States, 38801
United States, Missouri
Ironwood Investigational Site
Jefferson City, Missouri, United States, 65109
United States, New Jersey
Ironwood Investigational Site
Marlton, New Jersey, United States, 08053
United States, New Mexico
Ironwood Investigational Site
Albuquerque, New Mexico, United States, 87108
United States, New York
Ironwood Investigational Site
Mineola, New York, United States, 11501
Ironwood Investigational Site
Pittsford, New York, United States, 14534
United States, North Carolina
Ironwood Investigational Site
Asheboro, North Carolina, United States, 27203
Ironwood Investigational Site
Asheville, North Carolina, United States, 28801
Ironwood Investigational Site
Chapel Hill, North Carolina, United States, 27599
Ironwood Investigational Site
Charlotte, North Carolina, United States, 28211
Ironwood Investigational Site
Charlotte, North Carolina, United States, 28209
Ironwood Investigational Site
Greensboro, North Carolina, United States, 27408
Ironwood Investigational Site
Greensboro, North Carolina, United States, 27401
Ironwood Investigational Site
Harrisburg, North Carolina, United States, 28075
Ironwood Investigational Site
Hickory, North Carolina, United States, 28602
Ironwood Investigational Site
Huntersville, North Carolina, United States, 28078
Ironwood Investigational Site
New Bern, North Carolina, United States, 28562
Ironwood Investigational Site
Statesville, North Carolina, United States, 28625
Ironwood Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Ironwood Investigational Site
Beachwood, Ohio, United States, 44122
Ironwood Investigational Site
Cincinnati, Ohio, United States, 45224
Ironwood Investigational Site
Cincinnati, Ohio, United States, 45242
Ironwood Investigational Site
Dayton, Ohio, United States, 45440
Ironwood Investigational Site
Mentor, Ohio, United States, 44060
Ironwood Investigational Site
Sylvania, Ohio, United States, 43560
Ironwood Investigational Site
Wadsworth, Ohio, United States, 44281
United States, Oklahoma
Ironwood Investigational Site
Oklahoma City, Oklahoma, United States, 73116
Ironwood Investigational Site
Yukon, Oklahoma, United States, 73099
United States, Pennsylvania
Ironwood Investigational Site
Lancaster, Pennsylvania, United States, 17604
Ironwood Investigational Site
Levittown, Pennsylvania, United States, 19056
Ironwood Investigational Site
Reading, Pennsylvania, United States, 19606
Ironwood Investigational Site
Sellersville, Pennsylvania, United States, 18960
Ironwood Investigational Site
Washington, Pennsylvania, United States, 15301
United States, South Carolina
Ironwood Investigational Site
Anderson, South Carolina, United States, 29621
Ironwood Investigational Site
Charleston, South Carolina, United States, 29414
Ironwood Investigational Site
Simpsonville, South Carolina, United States, 29581
Ironwood Investigational Site
Summerville, South Carolina, United States, 29485
United States, Tennessee
Ironwood Investigational Site
Bristol, Tennessee, United States, 37620
Ironwood Investigational Site
Chattanooga, Tennessee, United States, 37404
Ironwood Investigational Site
Germantown, Tennessee, United States, 38183
Ironwood Investigational Site
Kingsport, Tennessee, United States, 37660
Ironwood Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
Ironwood Investigational Site
Beaumont, Texas, United States, 77701
Ironwood Investigational Site
El Paso, Texas, United States, 79905
Ironwood Investigational Site
Fort Worth, Texas, United States, 76104
Ironwood Investigational Site
Houston, Texas, United States, 77024
Ironwood Investigational Site
Irving, Texas, United States, 75061
Ironwood Investigational Site
Longview, Texas, United States, 75605
Ironwood Investigational Site
San Antonio, Texas, United States, 78229
Ironwood Investigational Site
Sugarland, Texas, United States, 77479
United States, Utah
Ironwood Investigational Site
Ogden, Utah, United States, 84405
Ironwood Investigational Site
Salt Lake City, Utah, United States, 84107
United States, Virginia
Ironwood Investigational Site
Chesapeake, Virginia, United States, 23320
Ironwood Investigational Site
Lynchburg, Virginia, United States, 24502
United States, Washington
Ironwood Investigational Site
Spokane, Washington, United States, 99208
Ironwood Investigational Site
Vancouver, Washington, United States, 98664
United States, Wisconsin
Ironwood Investigational Site
La Crosse, Wisconsin, United States, 54601
Ironwood Investigational Site
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
Ironwood Pharmaceuticals, Inc.
Forest Laboratories
Investigators
Study Chair: Jeffrey M. Johnston, MD, FACP Ironwood Pharmaceuticals, Inc.
  More Information

No publications provided by Ironwood Pharmaceuticals, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ironwood Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00938717     History of Changes
Other Study ID Numbers: MCP-103-302
Study First Received: July 12, 2009
Results First Received: September 28, 2012
Last Updated: October 9, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Ironwood Pharmaceuticals, Inc.:
IBS

Additional relevant MeSH terms:
Constipation
Irritable Bowel Syndrome
Signs and Symptoms, Digestive
Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on July 29, 2014